Ken Griffin Stock Portfolio: 10 Stocks to Buy

3. Boston Scientific Corporation (NYSE:BSX)

Citadel Investment Group’s Stake: $820.6 million

Boston Scientific Corporation (NYSE:BSX), based in Delaware, operates as a biomedical and biotechnology engineering firm and a global producer of medical devices used across various interventional medical specialties. These include interventional radiology, interventional cardiology, peripheral interventions, and oncology.

The company has reported robust growth in its cardiology segment, with U.S. sales rising by 27% and international sales by 18%, driven by strong performances in its ICTx and EP business sectors, as well as the Watchman franchise. In addition, some of the company’s recent product approvals include the Faraview mapping software and Farawave Nav catheter. Moreover, although the Acurate platform did not meet its primary endpoint in the Acurate IDE trial, it achieved a 20% revenue growth in EMEA, exceeding $200 million.

On November 5, TD Cowen reaffirmed its Buy rating and $100 price target for Boston Scientific Corporation (NYSE:BSX) after the company’s announcement of plans to acquire Cortex, a private firm known for its OptiMap system, a unique cardiac mapping tool for managing complex atrial fibrillation cases. TD Cowen emphasized the strategic value of this acquisition, as it is expected to enhance Boston Scientific’s already successful electrophysiology portfolio.